Welcome to our dedicated page for Nascent Biotech news (Ticker: NBIO), a resource for investors and traders seeking the latest updates and insights on Nascent Biotech stock.
Nascent Biotech, Inc. (NBIO) generates news primarily through developments in its clinical programs, collaborations, and corporate updates related to its lead monoclonal antibody candidate, Pritumumab (PTB). As a clinical-stage biotechnology company focused on cancer therapeutics, many of its announcements center on progress in brain cancer research, particularly glioblastoma, and on regulatory and scientific milestones.
News coverage for NBIO often highlights key clinical events, such as completion and presentation of Phase I trial data, FDA clearance to begin Phase II clinical trials for brain cancer, and updates on Phase II planning and study design. The company also issues press releases when it presents data at major scientific meetings, including poster presentations that summarize safety findings and early signs of biological activity.
Another important category of Nascent Biotech news involves strategic collaborations. The company has announced a research collaboration with Manhattan BioSolutions to explore antibody-drug conjugates using Pritumumab as the targeting antibody, and a collaboration with HypoSpray Pharma to investigate alternative transdermal and transmucosal delivery approaches for PTB. These stories provide insight into how Nascent aims to expand PTB’s potential applications and delivery options.
Investors following NBIO will also see corporate and capital-structure updates, such as the company’s disclosure that it fully repaid a variable convertible note to remove related dilution risk, and its later notice about a filing delinquency that led to quotation on the OTC Markets’ Expert Market. Together, these news items offer a view into both the scientific and financial aspects of Nascent Biotech’s development. This page aggregates such releases so readers can track clinical progress, partnership activity, regulatory milestones, and trading-status updates over time.
Nascent Biotech, Inc. (OTCQB:NBIO) has submitted the Protocol for its Phase 2 clinical trials of Pritumumab (PTB) to the FDA for review, marking a crucial step in advancing treatment for brain cancers.
The submission includes data from the Phase 1 Clinical Research focused on the safety and tolerance of PTB. This natural human antibody is designed to target and bind to vimentin, a protein found on epithelial cancer cells, thereby offering a targeted approach to immunotherapy.
The Company expects initial feedback from the FDA within 30 days of the submission. Nascent Biotech is dedicated to developing monoclonal antibodies aimed at treating various cancers and viral infections.
Nascent Biotech, a clinical-stage biotechnology company specializing in brain cancer treatments, has successfully completed its Phase I clinical trial for Pritumumab (PTB). This trial focused on evaluating safety and tolerance for patients with primary and metastatic brain cancers. The completion marks a significant milestone for the company, which is eager to analyze data and prepare for a Phase II submission to the U.S. FDA. PTB, a monoclonal antibody that targets cancer cells without harming healthy tissues, represents a novel approach in cancer treatment. The company aims to leverage its unique research and development platform for impactful solutions in the oncology space.
Nascent Biotech (OTCQB:NBIO) has concluded the dosing period for its Phase I Clinical Trial of Pritumumab (PTB), targeting brain cancer treatment. This marks the completion of the fifth and final cohort, focusing on safety and dose tolerance. The company is preparing to submit trial data and a Phase II Clinical Protocol to the FDA for review. PTB is a human antibody that specifically targets cancer cells by binding to a protein called Vimentin, sparing healthy cells. As the trial remains open for active participants, more data on PTB's safety and tolerability will be forthcoming.
Nascent Biotech (OTCQB:NBIO) has successfully completed enrollment for the final cohort of its Phase I trial evaluating Pritumumab (PTB) for brain cancer treatment. This marks an important milestone, paving the way for preparations to submit research data to the FDA for Phase II clinical trials. PTB, a monoclonal antibody, targets cancer cells while sparing healthy ones, offering a novel approach to cancer treatment. The company aims to advance its biologic asset with the goal of improving outcomes for patients faced with brain cancer.
Nascent Biotech, Inc. (OTCQB:NBIO) announced the appointment of Dr. Ivan Babic to its scientific advisory board. Dr. Babic, with over 14 years of experience in translational oncology, is currently the Director of Gilman Biosciences. His background includes significant roles at UCLA, UCSD's Moores Cancer Center, and the John Wayne Cancer Institute, focusing on novel glioblastoma therapeutics. CEO Sean Carrick expressed enthusiasm about Dr. Babic's expertise contributing to the company's growth in developing monoclonal antibodies for cancer treatment.
Nascent Biotech, Inc. (OTCQB:NBIO) announced the issuance of U.S. Patent No. 11,492,394 for their lead candidate Pritumumab on November 8, 2022. The patent, titled KITS AND CONTAINERS FOR TREATING VIMENTIN EXPRESSING TUMORS, affords extensive protection for Pritumumab, which targets vimentin expressed on epithelial cancers. CEO Sean Carrick highlighted that this patent enhances their intellectual property portfolio and signifies progress in their ongoing Phase I trial. Nascent Biotech focuses on developing monoclonal antibodies for cancer treatment.
Nascent Biotech (OTCQB:NBIO) announced the enrollment of the first patient in the fifth and final cohort of its Phase I clinical trial for Pritumumab (PTB), targeting primary and metastatic brain cancers. This marks a critical milestone as the company prepares to transition to Phase II research post-trial completion. The trial focuses on utilizing PTB, a human antibody that selectively targets cancer cells via cell surface vimentin, ensuring minimal damage to healthy tissues. Patient enrollment is ongoing, and interested individuals can find details on clinicaltrials.gov.
Nascent Biotech (OTCQB:NBIO) announced the completion of the Fourth Cohort in its Phase I trial for Pritumumab (PTB), a treatment targeting brain cancer. This milestone allows the trial to advance to the Fifth Cohort, with patient enrollment ongoing. Encouraging data from the four cohorts will support an upcoming FDA submission for Phase 2 research. PTB is designed as a targeted immunotherapy, aiming to selectively attack cancer cells while preserving healthy ones. The trial's progress is a significant step toward commercialization.
FAQ
What is the current stock price of Nascent Biotech (NBIO)?
What is the market cap of Nascent Biotech (NBIO)?
